TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05281172

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided Self-Change therapy (GSC)
Description: The GSC program follows a motivational cognitive-behavioral approach designed to minimize resistance in drug behavior changes, prevent relapse risk, and increase motivation to quit. The GSC consists of 5 weekly sessions of 50 minutes delivered in groups of 20-25 people.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation program about healthy habits
Description: The psychoeducational program will include talks about healthy habits such as physical activity, relaxation, and sleep hygiene. This intervention consists of 5 weekly sessions of 50 minutes delivered in groups of 20-25 people.
Study: NCT06442891

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupressure Therapy
Description: Self-administer relaxing acupressure
Study: NCT06444347

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hiatal Hernia Repair
Description: The non-mesh group will undergo hiatal hernia repair with permanent suture only.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hiatal Hernia Repair
Description: The non-mesh group will undergo hiatal hernia repair with permanent suture only.
Study: NCT05659992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azacytidine;cytarabine;aclamycin;Chidamide;venetoclax;granulocyte
Description: 1. azacytidine (75 mg/m2/day, days 1 to 7).~2. cytarabine (75 mg/m2 bid, days 1 to 5).~3. aclamycin (10 mg/m2/day, day1,3,5).~4. Chidamide (30 mg/day , days 0,3).~5. venetoclax (100 mg day 1, 200 mg day 2, 400mg days 3 to 14 ).~6. granulocyte colony-stimulating factor (5ug/kg/day, day 0 until agranulocytosis recovery)
Study: NCT05211518

Intervention type: OTHER
Group type: OTHER
Intervention: Tasty&Healthy
Description: exclude pro-inflammatory dietary components

Intervention type: OTHER
Group type: OTHER
Intervention: Habitual diet
Description: subjects will continue their habitual diet.
Study: NCT05555758

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adamgammadex Sodium
Description: Aom0319 will be administered intravenously with water for injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Sodium Chloride Injection
Description: 0.9% Sodium Chloride will be administered intravenously.
Study: NCT04766073

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Niche prevention suture
Description: This group will have the uterus sutured in two layers using a new technique.
Study: NCT06553313

Intervention type: DEVICE
Group type: OTHER
Intervention: Micro-Western Array
Description: The subjects first took the energy measurement of the pulse sphygmograph and Ryodoraku, rested for 20 minutes, and then repeated the measurements again. In order to comply with the acupuncture treatment course was 5 weeks in the previous study, we have two blood draw point. Each subject's blood was drawn for the first time, and then for the second time in 5 weeks later. Each subject drew 10ml of blood each time. The blood samples are analyzed by Micro-Western Array (MWA) and Enzyme-linked immunosorbent assay (ELISA) to obtain the serum protein content value of healthy individuals.
Study: NCT06144697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986465
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986465
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986465
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986465
Description: Specified dose on specified days
Study: NCT04723108

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Destek V4 Virtual Reality Headset
Description: The DESTEK V4 is a smartphone VR headset made by DESTEK, a manufacturer based in the US. This mobile virtual reality headset is compatible with most iOS and Android smartphones, as long as their screen size is between 4.5 and 6.
Study: NCT06144697

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Specified dose on specified days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Specified dose on specified days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegasys
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine
Description: Specified dose on specified days
Study: NCT06107413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-400
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-400
Description: Intravenous (IV) Infusion
Study: NCT05416151

Intervention type: OTHER
Group type: OTHER
Intervention: Freeze-dried biotic
Description: 2 sticks of 3g consumed daily for 28 days

Intervention type: OTHER
Group type: OTHER
Intervention: Maltodextrin
Description: 2 sticks of 3g consumed daily for 28 days
Study: NCT06442891

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Acupressure Therapy
Description: Self-administer sham acupressure

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-Based Intervention
Description: Receive access to acupressure mobile app

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Internet-Based Intervention
Description: Receive access to acupressure mobile app

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Interview
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Device Usage and Evaluation
Description: Receive an AcuWand

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Medical Device Usage and Evaluation
Description: Receive an AcuWand

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05749211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Huaier granule
Description: Oral administration, 20 g once, 3 times a day, continued until progression or intolerance of toxicity
Study: NCT06300632

Intervention type: OTHER
Intervention: geriatric locomotive syndrome
Description: Elderly individuals will be included in the study. Before each elderly person starts the study, they will be informed about the content of the study and they will read and sign the consent form stating that they participate in the study voluntarily. Socio-demographic data (age, body mass index, and family history, fall history, ) of all individuals participating in the study will be recorded.Within the scope of the evaluation, locomotive syndrome evaluation will be made through a survey. Fear of movement will be evaluated with the Tampa kinesiophobia scale, your physical activity level with the physical activity scale for the elderly, your physical performance with the short physical performance battery, your fatigue level with the fatigue severity scale, and your cognitive functions with the Montreal Cognitive Assessment Scale.
Study: NCT05178654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]PF-07321332
Description: Single oral dose of 300 mg \[14C\]PF-07321332 containing approximately 100 µCi \[14C\]PF-07321332 coadministered with 100 mg ritonavir.
Study: NCT05005078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WST-057
Description: WST-057 topical solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: WST-057 Matching placebo
Study: NCT06418750

Intervention type: OTHER
Group type: OTHER
Intervention: dermo-cosmetic product
Description: For patients in the preventive group, treatment with hand serum, gloves/slippers and fortifying solution/dissolving oil will be started on the day of the first administration of Ac bispecific. In the curative group, treatment will begin on inclusion in the study and will be adapted to the lesions present on D0. Treatment will be readjusted on a weekly basis according to the lesions present at the time of the follow-up visit.
Study: NCT06240728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPX887
Description: NPX887 will be administered by IV infusion every 3 weeks until documented disease progression or participant withdrawal for up to 2 years
Study: NCT05069415

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Eyhance IOL
Description: Intraocular lens replaces the natural lens removed during cataract surgery in both eyes. Target emmetropia OU.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eyhance IOL
Description: Intraocular lens replaces the natural lens removed during cataract surgery in both eyes. Target emmetropia OU.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Eyhance IOL
Description: Intraocular lens replaces the natural lens removed during cataract surgery in both eyes. Target mini monovision in the non-dominant eye.
Study: NCT05069415

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eyhance IOL
Description: Intraocular lens replaces the natural lens removed during cataract surgery in both eyes. Target mini monovision in the non-dominant eye.
Study: NCT06286072

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education and message
Description: COPD general education content and fatigue-specific coping strategies. Messages sent to phones

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education and message
Description: COPD general education content and fatigue-specific coping strategies. Messages sent to phones

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education and message
Description: COPD general education content and fatigue-specific coping strategies. Messages sent to phones
Study: NCT04775108

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Epygon™ Transcatheter Mitral Valve System
Description: The EPYGON VALVE is an innovative mitral valve, intended for valve replacement of a native mitral valve through a minimally invasive implant procedure by means of a dedicated implant device.~The EPYGON VALVE is a bio prosthesis, composed by a functional assembly of bovine pericardium on a NiTinol stent.
Study: NCT05057546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH antagonist
Description: GnRH antagonist will be given once for premenopausal women (12-week intervention) and twice for postmenopausal women (24-week intervention)
Study: NCT06570668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDD-2101
Description: All subjects will receive 4 sachets of CDD-2101 and/or placebo at a time based on the computer-generated randomization. An unblinded pharmacist will mix the assigned dose of CDD-2101 and/or placebo with 400 mL of water at 70-80°C, cool it to a comfortable temperature and keep it at room temperature for not longer than 1 h. A blinded study nurse or investigator will dispense the suspension to the assigned subject. The subject will drink it under supervision within 15 minutes.
Study: NCT05854199

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth solution
Description: Telehealth nutrition education platform
Study: NCT05621551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: The patients is required to receive dapagliflozin(10mg, q.d.) at least for 3 days until 24 hours before the surgery. Then dapagliflozin will be discontinued and recovered as soon as the patient is able to take oral diet postoperatively. Dapagliflozin wil be ceased five days after surgery.
Study: NCT04676217

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative positioning advice
Description: The postoperative positioning advice until 3 am the same day.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Postoperative positioning advice
Description: The postoperative positioning advice until 3 am the same day.
Study: NCT06051409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olverembatinib
Description: Orally, once every other day (QOD).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imatinib
Description: Orally, once daily (QD).
Study: NCT05360849

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Practice Facilitation
Description: Participating clinics will work with a Practice Facilitator to modify clinic processes to improve delivery of PrEP to women who inject drugs
Study: NCT05400798

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adipose Derived Regenerative Cells
Description: single injection of adipose-derived regenerative cells (ADRCs) into the partial-thickness rotator cuff tear

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid
Description: a single corticosteroid injection into the associated subacromial space
Study: NCT05846256

Intervention type: OTHER
Intervention: Sperm DNA Fragmentation
Description: Sperm DNA Fragmentation analysis.

Intervention type: OTHER
Intervention: Sperm DNA Fragmentation
Description: Sperm DNA Fragmentation analysis.
Study: NCT06350773

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tadalafil 20 mg then 40 mg if tolerated
Description: Patients will receive tadalafil for 12 week follow up period, in addition to the conventional anti failure therapy.
Study: NCT05663268

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infliximab-dyyb biosimilar
Description: Remsima for subcutaneous injection is a biosimilar monoclonal antibody of infliximab-dyyb that inhibits the activity of tumour necrosis factor (TNF)-alpha.
Study: NCT06065423

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manuel Lymphatic Drainage(MLD), Exercises
Description: MLD:It is a unique massage technique that uses specific hand movements to provide a gentle pumping effect on the skin.~Massage movements follow the direction of lymph flow and produce rapid results. The aim of this method is to achieve maximum skin tightening effect with minimum pressure.~Exercise, on the other hand, increases physical performance, improves body composition, and provides an increase in quality of life by providing acute and chronic reductions in fatigue. Both aerobic exercises and strengthening exercises have been found effective on physical performance. It shows that a mixed program consisting of components such as aerobics, strengthening, coordination and stretching can positively affect flexibility, pain and energy expenditure in breast cancer patients.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manuel Lymphatic Drainage(MLD), Exercises
Description: MLD:It is a unique massage technique that uses specific hand movements to provide a gentle pumping effect on the skin.~Massage movements follow the direction of lymph flow and produce rapid results. The aim of this method is to achieve maximum skin tightening effect with minimum pressure.~Exercise, on the other hand, increases physical performance, improves body composition, and provides an increase in quality of life by providing acute and chronic reductions in fatigue. Both aerobic exercises and strengthening exercises have been found effective on physical performance. It shows that a mixed program consisting of components such as aerobics, strengthening, coordination and stretching can positively affect flexibility, pain and energy expenditure in breast cancer patients.
Study: NCT05577871

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: infusion of dexmedetomidine during the off pump coronary artery bypass grafting surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: infusion of normal saline during the off pump coronary artery bypass grafting surgery
Study: NCT05478863

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral Placebo
Description: Placebo will be orally self-administered by study participants.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral THC
Description: THC will be orally self-administered by study participants.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral THC
Description: THC will be orally self-administered by study participants.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral THC
Description: THC will be orally self-administered by study participants.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral CBD
Description: CBD will be orally self-administered by study participants.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Caffeine
Description: Caffeine will be orally self-administered by study participants.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Caffeine
Description: Caffeine will be orally self-administered by study participants.
Study: NCT05237271

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Materials on the Cardiovascular Disease in Type 2 Diabetes (CVD-T2D)
Description: Educational Materials will detail the diagnostic tests in question. This CVD-T2D will provide a numerical risk score for the likelihood of patients with type 2 diabetes to have a cardiovascular event in the next 4 years.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Materials on the Cardiovascular Disease in Type 2 Diabetes (CVD-T2D)
Description: Educational Materials will detail the diagnostic tests in question. This CVD-T2D will provide a numerical risk score for the likelihood of patients with type 2 diabetes to have a cardiovascular event in the next 4 years.
Study: NCT05992480

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: rVSVDG-ZEBOV-GP Ebola Virus Vaccine (ERVEBO)
Description: It is an Ebola virus vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rVSVDG-ZEBOV-GP Ebola Virus Vaccine (ERVEBO)
Description: It is an Ebola virus vaccine
Study: NCT06408246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guanfacine
Description: Guanfacine immediate release is an established and safe FDA-approved treatment that acts directly by stimulating α2A adrenoceptors.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: Sertraline is a well-tolerated FDA-approved antidepressant that is among the most widely prescribed medications for depression.
Study: NCT06570668

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CDD-2101
Description: All subjects will receive 4 sachets of CDD-2101 and/or placebo at a time based on the computer-generated randomization. An unblinded pharmacist will mix the assigned dose of CDD-2101 and/or placebo with 400 mL of water at 70-80°C, cool it to a comfortable temperature and keep it at room temperature for not longer than 1 h. A blinded study nurse or investigator will dispense the suspension to the assigned subject. The subject will drink it under supervision within 15 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDD-2101
Description: All subjects will receive 4 sachets of CDD-2101 and/or placebo at a time based on the computer-generated randomization. An unblinded pharmacist will mix the assigned dose of CDD-2101 and/or placebo with 400 mL of water at 70-80°C, cool it to a comfortable temperature and keep it at room temperature for not longer than 1 h. A blinded study nurse or investigator will dispense the suspension to the assigned subject. The subject will drink it under supervision within 15 minutes.
Study: NCT06570811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets is supplied to breast cancer patients who receive 80 mg/ m2 paclitaxel (taxol®) chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 200mg twice daily
Description: 400 mg daily (200mg twice daily) of Coenzyme Q10 (an antioxidant that's in many foods, and it's made naturally in the investigator's bodies) is supplied to breast cancer patients who receive 80 mg/ m2 paclitaxel (taxol®) chemotherapy.
Study: NCT06569654

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Saebo splint
Description: The SaeboFlex orthosis was fitted individually for each participant in the intervention group. The orthosis was adjusted to ensure proper alignment and comfort.~Participants were instructed on how to don and doff the orthosis correctly and safely.~The orthosis positions the wrist and fingers in extension in preparation for grasp and release activities, enabling participants to perform functional tasks despite limited voluntary movement.~Task-Oriented Repetitive Training:~The intervention consisted of 45-minute sessions, conducted twice a week, over a period of 12 weeks.~Each session focused on repetitive, task-oriented exercises designed to improve motor function and enhance neuroplasticity.~Training Activities:~* Moving the Ball~* Bringing the Ball to the Mouth~* Reaching Towards a Target~* Manipulating the Ball Around a Target~* Placing the Ball into Tubes~* Throwing the Ball~* Catching a Rolling Ball
Study: NCT05237271

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Materials on the CVD-T2D and Bundled Metabolic Panel
Description: Educational Materials will detail the diagnostic tests in question.his CVD-T2D will provide a numerical risk score for the likelihood of patients with type 2 diabetes to have a cardiovascular event in the next 4 years. The bundled metabolic scores will provide insight into the patient's current metabolic conditions.
Study: NCT05411900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BoNT-A
Description: A vial of 500 units of BoNT-A will be reconstituted with 2 mL of saline solution (0.9%) and 1 mL of lidocaine solution (2%) to obtain a final concentration of BoNT-A of 166.6 units/mL.~Injections will be repeated at sites 1-1.5 cm apart (0.1 ml, 16.6 units per site), up to 20 sites (333 units).~To reduce pain caused by the injection, lidocaine and prilocaine cream will be applied to the skin area 60 min before the procedure. Additionally, ice could be applied for a few seconds (4-8) before each injection of 16.6 units of BoNT-A.~Injections will be repeated at week 0 and week 12.~The active treatment and placebo solutions will be transparent and indistinguishable to maintain treatment blindness.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will consist of equal volume of saline solution (0.9%). Injections will be repeated at sites 1-1.5 cm apart (0.1 ml, 16.6 units per site), up to 20 sites (333 units).~To reduce pain caused by the injection, lidocaine and prilocaine cream will be applied to the skin area 60 min before the procedure. Additionally, ice could be applied for a few seconds (4-8) before each injection.~Injections will be repeated at week 0 and week 12.~The active treatment and placebo solutions will be transparent and indistinguishable to maintain treatment blindness.